CHINA RESOURCES DOUBLE CRA

China Double CRA Trades Flat as NMPA Grants Baricitinib Approval for Subsidiary

China Double CRA stock stays flat at CNY 16.11 as Beijing Wanhui Double Crane secures NMPA approval for Baricitinib, boosting the pharma group’s outlook.

CHINA RESOURCES DOUBLE CRA
China
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Jake Connors

21/10/2026, 18:44

3 minutes to read

China Double Cra Holds Steady: Flat Trading, Solid Fundamentals & Low‑Risk Entry

China Double Cra’s stock stays flat at CNY 16.28, offering a low‑risk entry amid steady trading and solid pharmaceutical fundamentals.

CHINA RESOURCES DOUBLE CRA
China
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Samantha Roth

21/10/2026, 00:52

2 minutes to read